1	Integrative Omics Reveal Novel Protein Targets For Chronic Obstructive Pulmonary
2	Disease Biomarker Discovery
3	
4	Ana I Hernandez Cordero, ^{1*} Stephen Milne, ^{1,2,3*} Chen Xi Yang, ¹ Xuan Li, ¹ Henry Shi, ¹ Don D.
5	Sin, ^{1,2} and Ma'en Obeidat ¹
6	
7	1. The University of British Columbia Centre for Heart Lung Innovation, St Paul's Hospital,
8	Vancouver, BC, Canada
9	2. Division of Respiratory Medicine, University of British Columbia, Vancouver, BC, Canada
10	3. Faculty of Medicine and Health, University of Sydney, Camperdown, NSW, Australia
11	*First co-authors
12	Corresponding author:
13	Ana I Hernandez Cordero, PhD
14	Address: 1081 Burrard St Room 166, Vancouver, BC V6Z 1Y6
15	Email: <u>Ana.Hernandez@hli.ubc.ca</u>
16	
17	

18 Abstract

19 **Background:** Large genome-wide association studies (GWAS) and other genetic studies have

- 20 revealed genetic loci that are associated with chronic obstructive pulmonary disease (COPD).
- 21 However, the proteins responsible for COPD pathogenesis remain elusive. We used integrative-
- 22 omics by combining genetics of lung function and COPD with genetics of proteome to identify
- 23 proteins underlying lung function variation and COPD risk.
- 24 Methods: We used summary statistics from the GWAS of human plasma proteome from the
- 25 INTERVAL cohort (n=3,301) and integrated these data with lung function GWAS results from
- 26 the UK Biobank cohorts (n=400,102) and COPD GWAS results from the ICGC cohort (35,735

27 cases and 222,076 controls). We performed in parallel: a proteome-wide Bayesian colocalization,

and a proteome-wide Mendelian Randomization (MR) analyses. Next, we selected proteins that

- 29 colocalized with lung function and/or COPD risk and explored their causal association with lung
- 30 function and/or COPD using MR analysis (P < 0.05).
- 31 **Results:** We found 537, 607, and 250 proteins that colocalized with force expiratory volume in
- 32 one second (FEV₁), FEV₁/forced vital capacity (FVC), or COPD risk, respectively. Of these,
- 33 1,051 were unique proteins. The sRAGE protein demonstrated the strongest colocalization with
- 34 FEV₁/FVC and COPD risk, while QSOX2, FAM3D and F177A proteins had the strongest
- 35 associations with FEV₁. Of these, 37 proteins that colocalized with lung function and/or COPD,
- 36 also had a significant causal association. These included proteins such as PDE4D, QSOX2 and
- 37 RGAP1, amongst others.
- 38 **Conclusion:** Integrative-omics reveals new proteins related to lung function. These proteins may
- 39 play important roles in the pathogenesis of COPD.
- 40

41 Introduction

42 Chronic obstructive pulmonary disease (COPD) is a persistent respiratory condition that is 43 characterized by irreversible and progressive lung function impairment, and is responsible for 44 over three million deaths worldwide each year (Roth et al. 2018). Large genome-wide 45 association studies (GWAS) have revealed hundreds of genetic loci that are associated with COPD (Cho et al. 2014; Hobbs et al. 2017; Sakornsakolpat et al. 2019) and lung function more 46 47 generally (Shrine et al. 2019). However, the molecular mechanisms relating these genetic 48 associations to lung function and COPD pathogenesis remain elusive, hindering the ability to 49 translate these findings into new therapeutic targets or biomarkers of disease.

50 Integrative-omic methodologies may provide insights into the biological relationships 51 between genetic variants and complex traits such as lung function and COPD (Giambartolomei 52 et al. 2014; Gusev et al. 2016). These methods aim to establish a link between gene expression or 53 protein levels and the trait by leveraging their respective associations with common genetic 54 variants, which can be determined from independent cohorts. For example, the integration of 55 COPD GWAS with transcriptomic datasets suggests that the effects of many COPD risk loci are 56 mediated through regulation of gene expression in lung tissue (Obeidat et al. 2015; Lamontagne 57 et al. 2018).

58 Determining causal associations between molecular and complex traits are critical for 59 understanding disease pathogenesis, and for translating these molecules into biomarkers or 60 therapeutic targets. One method that has recently gained momentum in assessing causality of a 61 complex trait-molecular phenotype relationship is Mendelian Randomization (MR). The MR 62 framework exploits the random allocation of alleles during meiosis and relates their effects on a 63 putative risk factor, which can be a quantified by measuring biomolecules such as a blood 64 protein (Smith and Ebrahim 2003; Voight et al. 2012). This in turn can be related to a trait. MR 65 analysis measures the 'lifetime exposure' to this risk factor in a way that is relatively resistant to confounding from environmental influences or reverse causation. This enables an unbiased 66 67 assessment of causality. MR analysis has established causal associations between a number of candidate blood proteins and COPD (Milne et al. 2020). However, the application of MR 68 69 analysis at a genome-wide discovery level and by coupling it with integrative omics methods 70 will likely yield many additional novel protein associations with COPD.

71 In this study, we combined two approaches; MR analysis of plasma proteins and COPD 72 risk and genome-wide Bayesian colocalization (COLOC). We used both of these approaches to 73 integrate a large human plasma proteome dataset (Sun et al. 2018) with GWASs for lung 74 function in a general population (Shrine et al. 2019) and for COPD risk in a large case-control 75 dataset (Sakornsakolpat et al. 2019), to nominate promising protein targets for further 76 mechanistic biomarker exploration in and studies.

77 Results

78 Study design

79 The overall study design is shown in **Figure 1**. We aimed to identify plasma proteins causally associated with the following phenotypic traits: forced expiratory volume in one sec 80 (FEV₁); FEV₁ to forced vital capacity (FEV₁/FVC) ratio; and the presence of COPD (henceforth 81 82 referred to as 'COPD risk'). These associations were determined by integrating a human plasma 83 proteome GWAS (Sun et al. 2018) with the largest existing GWAS for lung function (Shrine et 84 al. 2019) and COPD (Sakornsakolpat et al. 2019). Each of these datasets (described in detail in the Methods) summarizes the association of millions of genetic variants (single nucleotide 85 86 polymorphisms [SNPs]) with their respective traits. We performed the study in two stages. Stage 87 1 was an unbiased discovery of proteins associated with the phenotypic traits, by performing two 88 integrative omics methods in parallel: a genome-wide COLOC analysis of each associated 89 genetic locus, and a genome-wide MR analysis of all measured proteins. Stage 2 was a step-wise 90 analysis, wherein we used only proteins that were significantly colocalized with one or more of the phenotypic parameters in subsequent, apply a hypothesis-driven MR threshold. From these 91 92 results, we generated a list of plasma proteins that showed a causal association with COPD risk 93 and/or lung function.



95 **Figure 1. Study design.** The diagram shows the workflow used to identify causal factors for lung 97 function and COPD risk. We selected as top plasma proteins those that showed significant colocalization 98 at $PP_{H4} > 0.80$ and causality at FDR < 0.10 or $P_{MR} < 0.05$ with lung function and/or COPD risk.

100 risk

In Stage 1, we used two integrative omics methods. We first performed a COLOC analysis across the 2,995 proteins, which were measured in the plasma proteome dataset. For this analysis, we included genetic loci associated with each of the clinical parameters (lung function traits and COPD) at a $P_{GWAS} < 5 \times 10^{-07}$ and set the significance of colocalization at $PP_{H4} > 0.80$.

In total, 1,048 unique proteins were colocalized with at least one of the COPD phenotypes. Of these, 447 protein colocalized at $PP_{H4} > 0.90$. For the lung function traits, 537 proteins colocalized with FEV₁; proteins with the highest PP_{H4} were sulfhydryl oxidase 2 (QSOX2) ($PP_{H4} = 0.99$), protein FAM3D (FAM3D) ($PP_{H4} = 0.99$) and FAM177A1 (F177A) ($PP_{H4} = 0.99$) (**Figure 2**). Likewise, 607 proteins colocalized with FEV₁/FVC; those with the

⁹⁹ Stage 1: a genome-wide discovery of plasma proteins associated with lung function and COPD

- 110 highest PP_{H4} included the advanced glycosylation end product-specific receptor (sRAGE) (PP_{H4}
- 111 = 0.99), stromelysin-2 (MMP-10) ($PP_{H4} = 0.99$) and collagen alpha-3(VI) ($PP_{H4} = 0.99$)
- 112 (Figure 2). We found that 200 unique proteins overlapped with both traits (Supplemental Table
- 113 **1**). For COPD risk, there were 250 colocalized proteins. Based on PP_{H4} , the top three colocalized
- 114 proteins were sRAGE ($PP_{H4} = 0.99$), C-C motif chemokine 14 (HCC-1) ($PP_{H4} = 0.99$), and AT-
- 115 rich interactive domain-containing protein 3A (ARI3A) ($PP_{H4}=0.99$) (Figure 2). Approximately
- half of proteins that were colocalized with COPD risk were also colocalized with FEV_1 (94/250)
- 117 or FEV_1/FVC (126/250) (**Supplemental Table 1**).



Figure 2. Bayesian colocalization (COLOC) analyses of the plasma proteome related to lung function (a and b) traits and chronic obstructive pulmonary disease (COPD) risk (c). The horizontal axis in each plot represents the chromosomal position of the plasma protein coding genes and the vertical axis shows the posterior probability of the two phenotypes (protein level and clinical trait) sharing a common genetic variant (PP_{H4}). Significant colocalization is defined as $PP_{H4} > 0.80$ (red dashed line).

124 Each purple or grey dot represents a plasma protein. Labelled colocalized proteins are those with 125 significant causal associations with the phenotypic trait at P < 0.05. Note: Plasma proteins are labelled 126 based on their protein coding gene names.

127

We next performed MR analyses for each of the 2,995 proteins present in the plasma proteome dataset (Sun et al. 2018). MR analysis uses genetic variants as instrumental variables to relate their per-allele effects on a risk factor to their per-allele effects on a phenotypic trait. MR therefore estimates the 'causal' effect of the risk factor on the phenotypic trait. For these analyses, we used a two-sample multivariable inverse variance weighted MR model (IVW-MR), and tested various MR assumptions (see Methods). Since this was a hypothesis-free analysis, we set a false discovery rate (FDR) of <0.1 to control for multiple comparisons.

135 For the lung function traits, three proteins – QSOX2, Rac GTPase-activating protein 1 136 (RGAP1) and NAD(P)H quinone dehydrogenase 1 (NOO1) – showed causal associations with 137 FEV_1 at FDR < 0.1 (**Table 1**). Testing of the MR assumptions showed no significant heterogeneity based on a Cochran's Q test (P > 0.05), or pleiotropy (Egger-MR intercept P > 0.05) 138 139 (0.05) for either protein. Based on the direction of the MR estimate, we inferred that increased plasma levels of QSOX2 and RGAP1 were associated with decreased FEV₁ (Table 1 and 140 141 Figure 3), while increased plasma level of NQO1 was associated with increased FEV₁ (Table 1). 142 None of the analysed proteins showed a significant causal association with FEV_1/FVC at FDR < 0.1. MHC class I polypeptide-related sequence B (MICB) showed a significant causal 143 association with COPD risk (Table 1) with no evidence of heterogeneity (P > 0.05) or 144 145 pleiotropy (Egger MR Intercept P > 0.05). The direction of effect was such that increased 146 plasma MICB level was associated with reduced COPD risk (Table 1 and Figure 3). None of 147 the proteins was causally associated with more than one COPD phenotype.

When we compared the results of the COLOC and hypothesis-free MR, we found that three proteins (QSOX2, RGAP1 and MICB) were identified by both methods at FDR < 0.1.

151Table 1. Causal association of plasma proteins with lung function and/or COPD risk from152hypothesis-free MR analysis

Protein	Trait	Beta	SE	P-value	Het P-value
NQO1	FEV_1	0.02	0.004	2.88×10^{-08}	0.44
RGAP1	FEV ₁	-0.04	0.005	6.49×10 ⁻¹⁵	0.20
QSOX2	FEV ₁	-0.02	0.003	5.85×10 ⁻¹¹	0.44
MICB	COPD risk	-0.15	0.018	9.98×10 ⁻¹⁷	0.16

Plasma protein with significant Mendelian randomization (MR) (FDR<0.10) for lung function and chronic obstructive pulmonary disease (COPD) risk. From left to right columns shows 1) the name of the protein; 2) trait used for the MR, 3) inverse variance weighting (IVW)-MR estimated effect; 4) IVW-MR standard error of the effect; 5) IVW-MR *P-value*; 6) Heterogeneity (Het) *P-value* of the SNPs used for the MR (Cochran's Q test), 7) trait that colocalized (COLOC) with plasma protein levels (posterior probability (*PP_{H4}*) of colocalization > 0.80). FEV₁: Forced expiratory volume in one second. ns: not significant.

160

161 *Stage 2: a step-wise discovery of plasma proteins that were causally associated with lung* 162 *function and/or COPD risk*

In Stage 2, we extracted the MR results for proteins showing significant colocalization 163 $(PP_{H4} > 0.8)$ with at least one of the phenotypes (537, 607, and 250 plasma proteins that 164 165 colocalized with FEV₁, FEV₁/FVC, and COPD risk, respectively). In this stage we considered 166 the MR result as a complement to the COLOC results; we therefore set the significance threshold 167 of the MR model at $P_{MR} < 0.05$. In total, 37 unique proteins showed a causal association with at 168 least one of the three phenotypic traits. These included 20 proteins associated with FEV_1 , 12 proteins associated with FEV₁/FVC, and 9 proteins associated with COPD (Table 2). None of 169 the significant results showed heterogeneity (P > 0.05) or pleiotropy (Egger MR Intercept P >170 171 0.05).

172 For FEV₁, the most significantly associated candidate protein was RGAP1 whose plasma 173 levels increased with decreasing FEV_1 (Figure 3). For FEV1/FVC, the most significantly 174 associated protein was cAMP-specific 3', 5'-cyclic phosphodiesterase 4D (PDE4D), whose 175 plasma levels increased with increasing FEV₁/FVC (Figure 3). For COPD risk, the most 176 significantly associated protein was MICB, whose plasma levels increased with decreasing 177 COPD risk (Figure 3). RGAP1 and MICB, but not PDE4D, were also identified with the 178 hypothesis-free MR approach (stage 1) with the same direction of effect for their respective 179 phenotypic traits.

180 There was some overlap between the proteins associated with each of the COPD 181 phenotypes. For example, increased plasma OSOX2 was associated with increased COPD risk and decreased FEV1 (Table 2). Increased plasma contactin-2 (CNTN2) was causally associated 182 with decreased FEV₁/FVC and increased COPD risk. None of the proteins tested were found to 183 184 association all phenotypic have a causal with three traits.

185 Highlighting potential candidate proteins

We nominated colocalized proteins having strong support for a causal association with lung function and/or COPD as candidate proteins. This list included proteins showing a significant MR estimate in Stage 2; for example, **Figure 3** shows the MR results for PDE4D, MICB and RGAP1; by nature of the step-wise analysis, these proteins were also significantly colocalized with one or more of the COPD traits. The full MR results for these proteins are provided in **Supplemental Table 2**.

Causal association				Colocalization			
	(Meno	delian randomiz	ation)				
Protein	$COPD$ Risk $\mathcal{B}(P_{2}, m)$	FEV_1	FEV_{1}/FVC	COPD risk	FEV ₁ PP ₁₁	FEV ₁ /FVC	
	$p(I_{MR})$	$p(I_{MR})$	$p(I_{MR})$	<u> </u>		<u> </u>	
LDE4D	(3.61×10^{-16})	-	(1.47×10^{-60})	0.85	0.91	0.04	
QSOX2	0.05	-0.02	-	-	0.99	-	
	(4.78×10^{-05})	(5.85×10^{-11})					
VEGF sR3	-0.09	-0.01	-	-	0.97	-	
CNITN ₂	(1.23×10^{-1})	(1.43×10^{-3})	0.03	0.95			
CIVIIN2	(9.14×10^{-04})		(5.46×10^{-11})	0.95	-	-	
MICB	-0.15	_	(5.40×10)	_		0.80	
MICD	(9.98×10^{-17})					0.00	
IL3-RA	-0.06	_	_	_	0.98	0.82	
	(3.21×10^{-05})				0.90	0.02	
CF126	0.129307	-	-	-	0.88	-	
	(2.47×10^{-03})						
NPC2	-0.03176	-	-	-	-	0.87	
	(8.69×10^{-03})						
SURF	-0.05146	-	-	0.85	-	-	
	(3.85×10^{-02})						
KI2S2	-	-0.05	-	0.88	-	-	
RGAP1		(3.01×10^{-1})		0.97			
KOAF I	-	(6.49×10^{-15})	_	0.97	-	_	
GP116	_	0.02	_	0.92	0.98	_	
		(4.42×10^{-11})					
sE-	-	0.02	-	-	0.98	-	
Selectin		(2.51×10^{-10})					
VEGF	-	0.03	-	-	0.98	0.89	
sR2		(2.58×10^{-10})					
C4	-	-0.02	-	-	0.92	0.84	
		(1.82×10^{-04})					
TIMP-4	-	0.02	-	-	-	0.94	
		(2.24×10^{-04})					
Cathepsin	-	0.01	-	-	0.93	-	
S		(3.54×10^{-04})		0.00			
LYZL2	-	-0.03	-	0.88	-	-	
ITI haaru		(4.82×10^{-1})			0.02		
chain H1	-	-0.01 (6.58×10 ⁻⁰⁴)	-		0.92	-	
VSIG2		(0.38×10^{-1})		0.86	0.01	0.90	
V5102	_	(7.01×10^{-04})	_	0.00	0.71	0.90	
BATF3	-	0.02	_	0.90	0.87	0.92	
		(7.78×10^{-04})		5.20	0.07	0.72	
sRAGE	-	-0.02	-	0.99	-	0.99	
-		(9.64×10 ⁻⁰⁴)					
INSL3	-	-0.03	-		-	0.90	
		(1.15×10 ⁻⁰³)					
C1GLC	-	-0.01	-	0.92	0.98	-	
		(1.49×10 ⁻⁰³)					
ESAM	-	0.02	-	_	0.81	-	

193 Table 2. Potential plasma protein targets associated with lung function and COPD

		(3.70×10^{-03})				
TM157	-	-0.03 (5.47×10 ⁻⁰³)	-	-	0.83	-
PPT1	-	-0.01 (8.25×10 ⁻⁰³)	-	-	-	0.88
AREG	-	-	-0.02 (1.05×10 ⁻⁰²)	0.91	-	-
RELB	-	-	-0.01 (1.36×10 ⁻⁰²)	-	-	0.85
PSD1	-	-	$\begin{array}{c} 0.01 \\ (1.59 \times 10^{-02}) \end{array}$	-	-	0.88
FCRL3	-	-	0.01 (1.59×10 ⁻⁰²)	0.87	-	-
KI3L2	-	-	-0.02 (1.93×10 ⁻⁰²)	-	0.81	-
TECK	-	-	$\begin{array}{c} 0.01 \\ (2.36 \times 10^{-02}) \end{array}$	-	0.99	-
FAM3D	-	-	-0.01 (2.37×10 ⁻⁰²)	-	0.99	0.82
BPI	-	-	-0.01 (3.03×10 ⁻⁰²)	0.98	-	-
CATZ	-	-	-0.01 (3.31×10 ⁻⁰²)	-	0.88	-
PH	-	-	0.02 (4.08×10 ⁻⁰²)	0.92	-	-

The table shows the proteins that were selected as potential candidates. From left to right column: 1) Protein symbol; 2) effect of plasma protein on Chronic Obstructive Pulmonary Disease (COPD) risk and IVW-MR *P-value*; 3) effect of plasma protein on and forced expiratory volume in one second (FEV₁) and IVW-MR *P-value*; 4) effect of plasma protein on FEV₁/FVC and IVW-MR *P-value*; 5) posterior probability of colocalization (*PP*_{H4}) between plasma protein levels and COPD risk; 6) *PP*_{H4} between plasma protein levels and FEV₁; 7) *PP*_{H4} between plasma protein levels and FEV₁/FVC.

200 201

202

203



205

206 Figure 3. Mendelian Randomization (MR) of protein biomarkers for lung function and Chronic 207 **Obstructive Pulmonary Disease (COPD) risk.** Inverse variance weighting (IVW) MR (IVW-MR) of 208 three plasma proteins on lung function and/or COPD risk. The figure shows the IVW-MR plot for PDE4D 209 (a and b), MICB (c) and RGAP1 (d). Dots represent the effect of the SNPs used for the IVW-MR on the 210 plasma protein levels (horizontal axis) and lung function traits or COPD risk (vertical axis). Estimates 211 were derived from 1) a plasma genome-wide association study (GWAS) for each protein, 2) GWAS of 212 the International COPD Genetics Consortium (ICGC) for COPD risk and 3) a Spirometry GWAS meta-213 analysis (UK biobank and SpiroMeta cohorts) for the forced expiratory volume in one second (FEV₁) and 214 FEV₁/Forced vital capacity (FVC). Error bars for each SNP represents the 95% confidence intervals. The 215 slope of the red line is the instrumental variable regression estimate of the effect of protein on the lung 216 function traits and/or COPD risk. IVW-MR *P-value* is shown at the top left corner of each MR plot.

218 **Discussion**

219 Translating COPD genetics findings into actionable biomarkers and therapeutic targets 220 requires understanding of the genes and proteins underlying the genetic associations. To our 221 knowledge, this is the largest integrative proteomics and GWAS for lung function and COPD to 222 date. The key findings were that: 1) the genetic loci associated with plasma levels of 1,048 and 223 250 unique proteins colocalized with lung function and COPD risk, respectively; 2) using an 224 standard MR approach, we identified 4 unique plasma proteins causally associated with lung 225 function and/or COPD risk; and 3) using an step-wise approach (COLOC coupled with MR) we 226 identified 37 candidates proteins for lung function and/or COPD.

227 By integrating lung function and COPD genetics and blood proteomics, we identified 228 537, 607, and 250 unique proteins, whose plasma levels significantly associated with FEV_1 , 229 FEV₁/FVC, or COPD risk, respectively. Of these, 74 were common to all three traits. This is a 230 substantial increase in the number of peripheral proteins associated with COPD phenotypes when 231 compared to previous reports, which had focused on candidate genes (Obeidat et al. 2017; Milne 232 et al. 2020). Our findings suggest that the expression levels of plasma proteins are associated 233 with lung function and COPD risk, supporting the notion that GWAS variants (even when 234 located within non-coding regions) have potential biological consequences that ultimately 235 contribute to the phenotypic variation of a complex trait or disease. Our findings could be used 236 as a starting point to support future biomarker and/or drug developmental studies. This is 237 particular true since targets with genetic support are more likely to be successful in drug 238 development (Nelson et al. 2015).

239 Of the proteins we identified in this study, there are several with known, biologically-240 plausible links to lung physiology and lung disease. For example, PDE4D is an isoenzyme that is 241 part of the phosphodiesterase subfamily 4 (PDE4 A-D), a group of proteins that are involved in 242 the pathogenesis of multiple inflammatory diseases, including but not limited to asthma and 243 COPD. Inhibition of PDE4 increases cAMP, which appears to have a positive effect in asthma 244 and COPD by decreasing lung inflammation (Huang and Mancini 2006) and inducing airway 245 smooth muscle relaxation (Méhats et al. 2003). PDE4 isoforms have different physiological roles 246 (Manning et al. 1999), and the specific role of the PDE4D isoform in lung pathology is not fully 247 understood. Importantly, pathological contribution may be tissue specific. For example, cigarette

exposure has opposite effects on PDE4D expression in alveolar compared to airway epithelial tissue (Zuo et al. 2019). In our study, PDE4D was measured in the plasma compartment, and the direction of the MR estimate suggested that increased PDE4D plasma levels were causally associated with increased lung function and reduced the risk of COPD. It is therefore plausible that a soluble form of PDE4D has different effects that the intracellular form or ones that are expressed in the local lung or immune cells. Further research is needed to understand the role of the soluble PDE4D in the pathophysiology of COPD.

255 Another interesting candidate we found was IL3-RA. Our results suggested that this 256 protein shares causal loci with lung function, and that increased plasma levels of IL3-RA are 257 associated with decreased risk of COPD. IL3-RA is one of the two subunits of the interleukin-3 258 (IL3) receptor, a cytokine produced mostly by T-cells and involved in several 259 immunopathologies (Hercus et al. 2013). IL3 signalling may be important for surfactant 260 homeostasis (Campo et al. 2012), alveolar macrophage function (Notarangelo and Pessach 261 2008), and activation and recruitment of eosinophils (George and Brightling 2016) (Davoine and 262 Lacy 2014). Surfactant homeostasis appears to be a contributing factor in obstructive lung 263 diseases, including asthma, COPD and cystic fibrosis (Devendra and Spragg 2002). Although 264 this concept has not been fully validated by experimental studies, it is plausible that soluble IL3-265 RA in plasma may disrupt IL3 signalling via competitive binding inhibition. This potential 266 function of IL3-RA in plasma may warrant further investigation especially in the context of COPD. 267

268 We found that increased sRAGE plasma protein levels were causally associated with 269 decreased lung function. sRAGE is the soluble isoform of the receptor for advanced glycation 270 end-products (RAGE). Under normal conditions this receptor is mainly expressed in lung tissue, 271 particularly in type I alveolar epithelial cells, and mediates proinflammatory responses (Buckley 272 and Ehrhardt 2010). sRAGE acts as a decoy for RAGE since it is capable of binding to RAGE 273 ligands, therefore inhibiting RAGE (Demling et al. 2006). Dysregulation of sRAGE has been 274 linked to COPD and lung function. Healthy individuals have been reported to have higher levels 275 of sRAGE compared to COPD patients (Gopal et al. 2012). In contrast, our results suggest that in 276 a general population increased sRAGE is linked to decreased lung function. This is in agreement 277 with a study of current smokers, where a missense variant in the gene encoding for RAGE was 278 associated with lower serum sRAGE levels and increased lung function (Miller et al. 2016).

Differential effects of sRAGE may therefore depend on an individual's genotype. To fully understand these conflicting results it is crucial to study RAGE regulation in COPD and in normal healthy individuals.

282 We also found that increased MICB levels were associated with decreased COPD risk. 283 Variants within the *MICB* gene have previously been associated with lung function (Soler 284 Artigas et al. 2011). MICB belongs to a major histocompatibility complex class I chain-related 285 (MIC) gene family (Bahram 2000). MICB is a cellular stress-induced molecule that contributes 286 to the innate and adaptive immune responses (Jamieson et al. 2002; Carapito and Bahram 2015). 287 Soluble MICB is decreased or undetectable in bronchial washes of smokers with normal lung 288 function and COPD patients compared to those of never-smokers (Roos-Engstrand et al. 2010). 289 This is in agreement with the direction of the MICB effect suggested by our study, and may 290 therefore be an interesting plasma protein candidate for further studies.

291 Our study has a number of limitations. First, the cohorts used for our analysis only 292 included white-European individuals; therefore the conclusions based on our results may not be 293 generalisable to populations of different ancestry. Second, our study was limited to the blood 294 plasma proteome. Since COPD is a systemic disease, studying the proteome of other tissues and 295 cell types may further elucidate the mechanisms underlying the GWAS associations. Third, the 296 2,995 proteins found in the INTERVAL Study data set represent ~15% of the whole human 297 proteome. It is probable that proteins not measured on this platform may contribute to the 298 phenotypic variability of the traits; these proteins remain undiscovered. Furthermore, it is likely 299 that other mechanisms that we did not explore (e.g. epigenetics and gene expression) could 300 contribute to COPD risk. Fourth, our integrative-omics approach only explored cis regions, 301 therefore future research should also evaluate the trans or distal regions associated with the traits. 302 Lastly, although our approach allowed us to prioritize a manageable set of proteins, further 303 efforts are necessary to validate the role of these peripheral proteins and their relationship to lung 304 function and COPD.

In summary, our integrative-omics approach revealed several novel plasma proteins that were significantly linked with COPD risk and/or lung function. Using a MR framework, we provide evidence suggesting that the plasma levels of multiple proteins have causal effects on these phenotypic traits. These proteins represent promising candidates for future development of

309 biomarkers and/or therapeutic targets in COPD and other lung pathologies associated with

310 reduced lung function.

311 Materials and methods

312 Datasets analysed for the current study

313 INTERVAL study

314 We analysed plasma protein quantitative trait loci (pQTL) obtained from the INTERVAL 315 study. The INTERVAL study was a randomized trial of blood donation intervals that comprises 316 around 45,000 participants that were recruited between June 11, 2012, and June 15, 2014 (Di 317 Angelantonio et al. 2017; Sun et al. 2018). The full details on the criteria for participants' 318 recruitment, informed consent, description of the cohort, sample collection, INTERVAL study 319 design, and objectives have been previously published (Di Angelantonio et al. 2017; Sun et al. 320 2018). Briefly, participants from the INTERVAL study were aged 18 years and older, in general 321 good health (based on blood donation criteria), and were recruited at 25 static donor centres of 322 NHS Blood and Transplant (NHSBT). Blood collection was performed using standard 323 venepuncture. Participants were genotyped for about 830,000 genetic variants using the 324 Affymetrix Axiom UK Biobank genotyping array and imputed to the 1000 Genome phase 3 UK10K reference panel. Genetic variants with imputation score $(r^2) > 0.7$, Hardy-Weinberg 325 Equilibrium (HWE) $P > 5 \times 10^{-06}$ and minor allele count of > 8 were retained (10,572,788 genetic 326 variants). A full description of the genotyping protocol and quality control has been previously 327 328 described (Astle et al. 2016).

329 After filtering out participants who failed to pass the genetic quality controls (HWE, minor allele count, r^2), a randomly-selected subset of 3,301 participants was used for the plasma 330 331 pQTL analyses of 2,995 plasma proteins levels. The protein levels were log-transformed and 332 adjusted for age, sex, waiting period between blood collection and processing and the first three 333 genetic principal components. The protein residuals then were extracted and rank-inverse 334 normalized. Later these residuals were used for genome-wide associations study (GWAS). The 335 genetic associations were tested with linear regression using an additive genetic model and the 336 results from each cohort were combined using a fixed-effect inverse-variance meta-analysis.

337 Significant associations were defined at $P < 1.5 \times 10^{-11}$. We used the totality of the pQTL results 338 (summary statistics) for the subsequent analyses described later in this section.

339

340 International COPD Genetics Consortium (ICGC) study

341 We determined the relationship between plasma proteins and COPD risk using the ICGC 342 dataset. The ICGC study is one of the largest COPD GWASs that has been conducted to date. 343 Briefly, this cohort included over 200,000 participants (35,735 cases and 222,076 controls) from 344 individual COPD GWASs (Sakornsakolpat et al. 2019). Each individual study obtained informed 345 consent from individual participants, and approval from the local human research 346 ethics/regulatory bodies (Cho et al. 2014; Hobbs et al. 2017; Sakornsakolpat et al. 2019). COPD 347 cases were defined based on pre-bronchodilator spirometry, with $FEV_1 < 80\%$ predicted and FEV₁ to FVC ratio of < 0.70. Controls were defined as FEV₁ > 80% predicted and FEV₁/FVC > 348 349 0.70. Each COPD GWAS was evaluated using logistic regression, which adjusted for age, sex, 350 pack-year of smoking, ever smoking status, current smoking status, and genetic ancestry 351 (principal component, as required for each study). The GWAS results were combined using a 352 fixed-effects meta-analysis. A full description of the cohort and study methods have been 353 previously published (Cho et al. 2014; Hobbs et al. 2017; Sakornsakolpat et al. 2019).

354

355 UK biobank and SpiroMeta lung function meta-analysis

We used genome-wide associations with lung function (FEV₁ and FEV₁/FVC) from a previously-published meta-analysis of the UK Biobank and SpiroMeta datasets (Shrine et al. 2019). This meta-analysis included 321,047 and 79,055 white European participants from the UK Biobank project (Bycroft et al. 2018) and the SpiroMeta consortium, respectively.

In the UK Biobank, phenotypic information was collected in 22 recruitment centres across the United Kingdom (Bycroft et al. 2018). Human research ethics approval for the UK Biobank project was granted by the North West Multi-centre Research Ethics Committee (MREC). Participants were genotyped with the Affymetrix Axiom UK BiLEVE and UK biobank array (Wain et al. 2015) and imputed to the Haplotype Reference Consortium panel; genotypes were retained if the minor allele count was \geq 3 and imputation r²>0.5 (Bycroft et al. 2018).

Association testing was conducted between genome-wide-significant genotypes and lung function traits (FEV₁ and FEV₁/FVC) using a linear mixed model (LMM), assuming additive genetic effects (Loh et al. 2015). The LMM was adjusted for confounders (age, age^2 , sex, height, smoking status, and genotyping array) (Shrine et al. 2019).

370 The SpiroMeta consortium includes participants from 22 individual studies, which have 371 been previously described (Shrine et al. 2019). Approval was granted for each individual study 372 from their respective local human research ethics committees. Participants were genotyped 373 according to the protocol described in each of the studies; 13 studies were imputed to the 1000 374 Genomes Project Phase 1 panel (1000 Genomes Project Consortium et al. 2010) and nine to the 375 Haplotype Reference Consortium panel (McCarthy et al. 2016). Genotypes with imputation 376 $r^2 < 0.30$ were excluded from further analysis (Shrine et al. 2019). For each individual study, 377 genetic associations with FEV_1 and FEV_1/FVC were determined using a linear regression model adjusted for age, age², sex and height. Genetic principal components were included as covariates 378 379 in studies of unrelated participants, while LMM were used in studies of related participants to 380 account for kinship and population structure. The results across all studies in the SpiroMeta 381 consortium were combined using an inverse-variance weighted meta-analysis. Shrine and 382 colleagues (Shrine et al. 2019) then combined the UK Biobank and SpiroMeta GWAS results 383 using an inverse-variance-weighted fixed-effects meta-analysis. In total, 19,819,130 genetic 384 variants (imputed or genotyped) in both cohorts (UK biobank and SpiroMeta consortium) were 385 used for the meta-analysis. The LD regression score intercept was close to 1(Shrine et al. 2019), 386 therefore no genomic control was applied.

387

388 Integrative -omics methods

389 Bayesian colocalization (COLOC).

We used COLOC to determine whether the associations between lung function traits (FEV₁, FEV₁/FVC, and COPD risk) and plasma protein levels were consistent with a causal variant (colocalization). We performed the analysis using the coloc package (Giambartolomei et al. 2014) implemented in R (R Core Team 2018). We evaluated the summary statistics for 3,248 plasma pQTLs (Sun et al. 2018) from the INTERVAL study. We included all SNPs associated with lung function (FEV₁ or FEV₁/FVC) in the UK Biobank/SpiroMeta GWAS meta-analysis

(19,819,130) (Shrine et al. 2019) and all SNPs associated with COPD risk in the ICGC dataset
(6,224,355) . In order to maximise the number of variants tested per genomic locus, which
overlapped across these studies, we did not set an *a priori* p value threshold for inclusion.

The COLOC method used for our research calculates the posterior probability (PP) of 399 400 colocalization of lung function (or COPD risk) and plasma protein-associated variants within a 401 defined genomic region. In summary, a large PP is supportive evidence of a single shared causal 402 variant for the two traits. For this test we applied the following parameters: 1) a prior probability of a SNP being associated with the lung function trait or plasma protein level to 1×10^{-04} ; and 2) a 403 404 prior probability of a SNP being associated with the lung function trait and plasma protein level to 1×10^{-06} . All SNPs across the genome were assumed to have equal prior probabilities (as set 405 406 before). In addition, we defined loci to be tested as genomic regions \pm 0.5 Mb windows 407 surrounding the top lung function-associated (or COPD risk-associated) variants. As a result, we 408 applied COLOC to 988,183 loci for FEV₁, 1,109,654 for FEV₁/FVC and 282,338 for COPD risk. 409 We placed the significance threshold of the COLOC analysis to be $PP_{H4} > 0.80$.

410 Mendelian Randomization

411 We used a MR approach to identify causal relationships between plasma proteins 412 ("exposure") and the three traits (FEV₁, FEV₁/FVC, and COPD risk; "traits"). We first identified 413 pQTLs for each of the selected proteins in the INTERNAL study by extracting the effect size 414 (Beta) and standard error (SE) of each variant that at least reached the arbitrary threshold of P< 5×10^{-06} and excluded the variants that were found within a 2Mb window(± 1Mb) to avoid 415 416 linkage. Next, we examined the complex trait associations in the UK Biobank/SpiroMeta meta-417 analysis (FEV₁, FEV₁/FVC) and ICGC (COPD risk) for these variants and, if present, extracted 418 the Beta value and SE for each. We then used these genetic variants as instrumental variables 419 (IVs) in a MR analysis. The fundamental assumptions of MR analysis are: 1) that the IVs are 420 associated with the exposure; 2) that the selected IVs only affect an outcome via the exposure; 421 and 3) that the IVs are independent of confounders. Using two MR methods, inverse variance 422 weighting (IVW) MR (IVW-MR) and Egger-MR we aimed to identify causal risk factors. For 423 each exposure-outcome pairing, we used an inverse variance weighted linear regression model 424 (IVW-MR) to relate the per-allele SNP association with the exposure to its association with the 425 trait. IVW-MR assumes no directional pleiotropy (i.e. genetic variant associated with multiple

426 unrelated phenotypes) by constraining the intercept to zero, and accounts for linkage 427 disequilibrium (LD) between genetic variants, heterogeneity was assessed based on the 428 Cochran's Q test (P < 0.05) that is part of the IVW-MR outcome (Burgess et al. 2016). We also 429 performed Egger-MR, which accounts for directional pleiotropy by un-constraining the intercept 430 (Bowden et al. 2015).

Based on this workflow, we identified a protein as having a causal association with the complex trait if the IVW-MR estimate was significant FDR < 0.1 and the Egger-MR intercept was not different from zero (P > 0.05). In addition, using an *a priori* hypothesis that the colocalized proteins were causally related to lung function traits and/or COPD, we determined their significant causal associations based on the IVW-MR threshold of $P_{MR} < 0.05$ and Egger-MR intercept P > 0.05.

437

438 Potential Biomarkers

Using the workflow described in **Figure 1**, we aimed to develop a list of potential candidate proteins that warrant further investigation for their role in lung function and/or COPD pathogenesis. We selected as top plasma proteins those that showed both significant colocalization at $PP_{H4} > 0.80$ and $P_{MR} < 0.05$ with lung function and/or COPD risk.

443 Article information

444

445 Data availability: All data used for these analyses are publicly available at:
446 <u>http://www.phpc.cam.ac.uk/ceu/proteins/; https://www.ebi.ac.uk/gwas/publications/30804560;</u>
447 and https://www.ebi.ac.uk/gwas/publications/30804561.

448

449 **Conflict of Interest:**

D.D.S. has received research funding from AstraZeneca for an investigator-initiated research
project and received honoraria for speaking engagements from Boehringer Ingelheim and
AstraZeneca over the past 36 months. S.M. reports personal fees from Novartis and BoehringerIngelheim, outside the submitted work.

- 455 Funding:
- 456 A.I.H.C. and S.M. are supported by MITACS accelerate and Providence Airway Centre
- 457

458 Acknowledgement:

- 459 Compute Canada computer cluster was used to conduct the data analyses.
- 460

461 **References**

- 462 1000 Genomes Project Consortium, Abecasis GR, Altshuler D, et al (2010) A map of human
 463 genome variation from population-scale sequencing. Nature 467:1061–1073.
 464 https://doi.org/10.1038/nature09534
- Astle WJ, Elding H, Jiang T, et al (2016) The Allelic Landscape of Human Blood Cell Trait
 Variation and Links to Common Complex Disease. Cell 167:1415-1429.e19.
 https://doi.org/10.1016/j.cell.2016.10.042
- Bahram S (2000) MIC genes: from genetics to biology. Adv Immunol 76:1–60.
 https://doi.org/10.1016/s0065-2776(01)76018-x
- Bowden J, Davey Smith G, Burgess S (2015) Mendelian randomization with invalid instruments:
 effect estimation and bias detection through Egger regression. Int J Epidemiol 44:512–
 525. https://doi.org/10.1093/ije/dyv080
- Buckley ST, Ehrhardt C (2010) The receptor for advanced glycation end products (RAGE) and
 the lung. J Biomed Biotechnol 2010:917108. https://doi.org/10.1155/2010/917108
- Burgess S, Dudbridge F, Thompson SG (2016) Combining information on multiple instrumental
 variables in Mendelian randomization: comparison of allele score and summarized data
 methods. Stat Med 35:1880–1906. https://doi.org/10.1002/sim.6835
- Bycroft C, Freeman C, Petkova D, et al (2018) The UK Biobank resource with deep phenotyping
 and genomic data. Nature 562:203–209. https://doi.org/10.1038/s41586-018-0579-z
- Campo I, Kadija Z, Mariani F, et al (2012) Pulmonary alveolar proteinosis: diagnostic and
 therapeutic challenges. Multidisciplinary Respiratory Medicine 7:4.
 https://doi.org/10.1186/2049-6958-7-4
- 483 Carapito R, Bahram S (2015) Genetics, genomics, and evolutionary biology of NKG2D ligands.
 484 Immunol Rev 267:88–116. https://doi.org/10.1111/imr.12328
- Cho MH, McDonald M-LN, Zhou X, et al (2014) Risk loci for chronic obstructive pulmonary
 disease: a genome-wide association study and meta-analysis. Lancet Respir Med 2:214–
 225. https://doi.org/10.1016/S2213-2600(14)70002-5

- 488 Davoine F, Lacy P (2014) Eosinophil cytokines, chemokines, and growth factors: emerging roles
 489 in immunity. Front Immunol 5:570. https://doi.org/10.3389/fimmu.2014.00570
- Demling N, Ehrhardt C, Kasper M, et al (2006) Promotion of cell adherence and spreading: a
 novel function of RAGE, the highly selective differentiation marker of human alveolar
 epithelial type I cells. Cell Tissue Res 323:475–488. https://doi.org/10.1007/s00441-0050069-0
- 494 Devendra G, Spragg RG (2002) Lung surfactant in subacute pulmonary disease. Respiratory
 495 Research 3:11. https://doi.org/10.1186/rr168
- 496 Di Angelantonio E, Thompson SG, Kaptoge S, et al (2017) Efficiency and safety of varying the
 497 frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors.
 498 Lancet 390:2360-2371. https://doi.org/10.1016/S0140-6736(17)31928-1
- George L, Brightling CE (2016) Eosinophilic airway inflammation: role in asthma and chronic
 obstructive pulmonary disease. Ther Adv Chronic Dis 7:34–51.
 https://doi.org/10.1177/2040622315609251
- Giambartolomei C, Vukcevic D, Schadt EE, et al (2014) Bayesian test for colocalisation between
 pairs of genetic association studies using summary statistics. PLoS Genet 10:e1004383.
 https://doi.org/10.1371/journal.pgen.1004383
- Gopal P, Rutten EPA, Dentener MA, et al (2012) Decreased plasma sRAGE levels in COPD:
 influence of oxygen therapy. Eur J Clin Invest 42:807–814.
 https://doi.org/10.1111/j.1365-2362.2012.02646.x
- 508Gusev A, Ko A, Shi H, et al (2016) Integrative approaches for large-scale transcriptome-wide509association studies. Nature Genetics 48:245–252. https://doi.org/10.1038/ng.3506
- Hercus TR, Dhagat U, Kan WLT, et al (2013) Signalling by the βc family of cytokines. Cytokine
 Growth Factor Rev 24:189–201. https://doi.org/10.1016/j.cytogfr.2013.03.002
- Hobbs BD, de Jong K, Lamontagne M, et al (2017) Genetic loci associated with chronic
 obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis.
 Nat Genet 49:426–432. https://doi.org/10.1038/ng.3752
- Huang Z, Mancini JA (2006) Phosphodiesterase 4 inhibitors for the treatment of asthma and
 COPD. Curr Med Chem 13:3253–3262. https://doi.org/10.2174/092986706778773040
- Jamieson AM, Diefenbach A, McMahon CW, et al (2002) The role of the NKG2D
 immunoreceptor in immune cell activation and natural killing. Immunity 17:19–29.
 https://doi.org/10.1016/s1074-7613(02)00333-3
- Lamontagne M, Bérubé J-C, Obeidat M, et al (2018) Leveraging lung tissue transcriptome to
 uncover candidate causal genes in COPD genetic associations. Hum Mol Genet 27:1819–
 1829. https://doi.org/10.1093/hmg/ddy091

- Loh P-R, Tucker G, Bulik-Sullivan BK, et al (2015) Efficient Bayesian mixed-model analysis
 increases association power in large cohorts. Nat Genet 47:284–290.
 https://doi.org/10.1038/ng.3190
- Manning CD, Burman M, Christensen SB, et al (1999) Suppression of human inflammatory cell
 function by subtype-selective PDE4 inhibitors correlates with inhibition of PDE4A and
 PDE4B. Br J Pharmacol 128:1393–1398. https://doi.org/10.1038/sj.bjp.0702911
- McCarthy S, Das S, Kretzschmar W, et al (2016) A reference panel of 64,976 haplotypes for
 genotype imputation. Nat Genet 48:1279–1283. https://doi.org/10.1038/ng.3643
- Méhats C, Jin S-LC, Wahlstrom J, et al (2003) PDE4D plays a critical role in the control of
 airway smooth muscle contraction. FASEB J 17:1831–1841.
 https://doi.org/10.1096/fj.03-0274com
- Miller S, Henry AP, Hodge E, et al (2016) The Ser82 RAGE Variant Affects Lung Function and
 Serum RAGE in Smokers and sRAGE Production In Vitro. PLoS One 11:.
 https://doi.org/10.1371/journal.pone.0164041
- Milne S, Li X, Cordero AIH, et al (2020) Protective effect of club cell secretory protein (CC-16)
 on COPD risk and progression: a Mendelian randomisation study. Thorax 75:934–943.
 https://doi.org/10.1136/thoraxjnl-2019-214487
- 540Nelson MR, Tipney H, Painter JL, et al (2015) The support of human genetic evidence for541approved drug indications. Nature Genetics 47:856–860. https://doi.org/10.1038/ng.3314
- 542 Notarangelo LD, Pessach I (2008) Out of breath: GM-CSFRα mutations disrupt surfactant
 543 homeostasis. Journal of Experimental Medicine 205:2693–2697.
 544 https://doi.org/10.1084/jem.20082378
- 545 Obeidat M, Hao K, Bossé Y, et al (2015) Molecular mechanisms underlying variations in lung
 546 function: a systems genetics analysis. Lancet Respir Med 3:782–795.
 547 https://doi.org/10.1016/S2213-2600(15)00380-X
- Obeidat M, Li X, Burgess S, et al (2017) Surfactant protein D is a causal risk factor for COPD:
 results of Mendelian randomisation. European Respiratory Journal 50:.
 https://doi.org/10.1183/13993003.00657-2017
- R Core Team (2018) R: A language and environment for statistical computing. R Foundation for
 Statistical Computing. https://www.r-project.org/. Accessed 5 Sep 2019
- Roos-Engstrand E, Pourazar J, Behndig AF, et al (2010) Cytotoxic T cells expressing the co stimulatory receptor NKG2 D are increased in cigarette smoking and COPD. Respiratory
 Research 11:128. https://doi.org/10.1186/1465-9921-11-128
- Roth GA, Abate D, Abate KH, et al (2018) Global, regional, and national age-sex-specific
 mortality for 282 causes of death in 195 countries and territories, 1980–2017: a

- systematic analysis for the Global Burden of Disease Study 2017. The Lancet 392:1736–
 1788. https://doi.org/10.1016/S0140-6736(18)32203-7
- Sakornsakolpat P, Prokopenko D, Lamontagne M, et al (2019) Genetic landscape of chronic
 obstructive pulmonary disease identifies heterogeneous cell-type and phenotype
 associations. Nat Genet 51:494–505. https://doi.org/10.1038/s41588-018-0342-2
- Shrine N, Guyatt AL, Erzurumluoglu AM, et al (2019) New genetic signals for lung function
 highlight pathways and chronic obstructive pulmonary disease associations across
 multiple ancestries. Nat Genet 51:481–493. https://doi.org/10.1038/s41588-018-0321-7
- Smith GD, Ebrahim S (2003) "Mendelian randomization": can genetic epidemiology contribute
 to understanding environmental determinants of disease? Int J Epidemiol 32:1–22.
 https://doi.org/10.1093/ije/dyg070
- Soler Artigas M, Loth DW, Wain LV, et al (2011) Genome-wide association and large-scale
 follow up identifies 16 new loci influencing lung function. Nat Genet 43:1082–1090.
 https://doi.org/10.1038/ng.941
- Sun BB, Maranville JC, Peters JE, et al (2018) Genomic atlas of the human plasma proteome.
 Nature 558:73–79. https://doi.org/10.1038/s41586-018-0175-2
- Voight BF, Peloso GM, Orho-Melander M, et al (2012) Plasma HDL cholesterol and risk of
 myocardial infarction: a mendelian randomisation study. Lancet 380:572–580.
 https://doi.org/10.1016/S0140-6736(12)60312-2
- 577 Wain LV, Shrine N, Miller S, et al (2015) Novel insights into the genetics of smoking behaviour, 578 lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic 579 association study in UK Biobank. Lancet Respir Med 3:769-781. 580 https://doi.org/10.1016/S2213-2600(15)00283-0
- 581ZuoH, FaizA, vandenBergeM, et al(2019)Cigarettesmokeexposurealters582phosphodiesterases in human structural lung cells.American Journal of Physiology-Lung583CellularandMolecularPhysiology318:L59–L64.584https://doi.org/10.1152/ajplung.00319.2019
- 585